Otulfi (ustekinumab or ustekinumab-aauz) is a biologic medication and a biosimilar to Stelara (ustekinumab). Like Stelara (ustekinumab), it's FDA approved to treat several autoimmune conditions, such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It works by lowering inflammation through blocking proteins in the body called interleukins. The medication is typically given as an injection under the skin, with doses spaced every 8 to 12 weeks based on your condition. Common side effects include tiredness, headache, and cold-like symptoms.
Moderate-to-severe plaque psoriasis (Ps) - adults and children 6 years and older
Psoriatic arthritis (PsA) - adults and children 6 years and older
Moderate-to-severe Crohn's disease (CD) - adults only
Moderate-to-severe ulcerative colitis (UC) - adults only
Otulfi (ustekinumab) is an interleukin antagonist. It works by blocking two proteins in your immune system — interleukin-12 (IL-12) and interleukin-23 (IL-23) — that play a major role in inflammation. By targeting these proteins, the medication helps to lower inflammation and relieve symptoms from autoimmune conditions.
Source: Prescribing Information
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Biosimilar that's interchangeable with Stelara (ustekinumab)
Syringes can be stored at room temperature for up to 30 days
Approved for children as young as 6 years old for certain conditions
Stopper isn't made of natural rubber latex
Can weaken your immune system and raise your risk of infection
Potential to cause serious allergic reactions
For CD and UC, the first dose must be given as an IV infusion
Can't receive live vaccines while taking this medication
Mark your injection dates on a calendar. You don’t use Otulfi (ustekinumab) very often, so it can be easy to forget. Keeping track helps you stay on schedule.
Inject Otulfi (ustekinumab) under the skin in your upper arms, thighs, buttocks, or stomach area. Pick a new spot each time to avoid skin irritation. Don’t inject into skin that’s red, bruised, sore, or hard.
Get medical help right away if you have signs of a serious allergic reaction after using Otulfi (ustekinumab). These might include swelling of the face or throat, trouble breathing, or a rash.
Otulfi (ustekinumab) can weaken your immune system, making it harder to fight infections. Let your prescriber know if you have symptoms of an infection, such as a fever, cough, tiredness, muscle aches, or stomach pain.
Contact your care team right away if you notice symptoms like headache, confusion, vision problems, or seizures. These could be signs of a rare brain condition linked to Otulfi (ustekinumab).
Otulfi (ustekinumab) can affect how your body responds to vaccines. Avoid live vaccines during treatment. Talk to your prescriber before getting any type of vaccine.
Store Otulfi (ustekinumab) in its original carton in the refrigerator. If you're using the prefilled syringes, you can keep them at room temperature (up to 30°C or 86°F) for up to 30 days, but don’t put them back once they've been out of the fridge. If you’re using a vial, it should stay refrigerated until it’s time for your dose.
How to inject Otulfi (ustekinumab) from a prefilled syringe:
Make sure you know how to inject Otulfi (ustekinumab) the right way. Ask your prescriber or pharmacist if you have questions.
Clean the spot on your skin with an alcohol wipe before you inject to help prevent infection.
When you're ready to inject, take off the needle cover from the syringe. Hold the syringe with one hand and pinch the cleaned skin with the other.
Insert the needle into the pinched skin at about a 45-degree angle and push the plunger down with your thumb until all the liquid is injected. Then take out the needle and let go of your skin.
Put the syringe into a sharps container. Never throw used syringes into the regular trash since it could harm someone.
Otulfi (ustekinumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Active, chronic, or recurrent infection | People with certain genetic mutations | Taking other medications that weaken your immune system
Otulfi (ustekinumab) can raise your risk of infections, including serious ones that might need hospital care. These can be caused by bacteria, viruses, or fungi. Tell your prescriber about your medical history before starting Otulfi (ustekinumab), especially if you've ever had tuberculosis (TB). Let your care team know right away if you have signs of infection, such as fever, chills, cough, or tiredness — your treatment might need to be paused until you recover.
Risk factors: Older adults | Taking other medications that weaken your immune system | History of skin cancer
Otulfi (ustekinumab) weakens your immune system and can raise your risk of certain cancers. Some people developed skin cancer while taking this medication, especially those with a higher risk. Your care team will check your skin regularly during treatment, particularly if you have a history of cancer or other risk factors. Let your prescriber know if you’ve had cancer before or if you notice any new or changing spots on your skin.
Serious allergic reactions, including anaphylaxis and angioedema, have been reported with Otulfi (ustekinumab). If you have a severe reaction, your care team will stop the medication and treat you right away. Get medical help immediately if you have symptoms like trouble breathing, swelling of your face or throat, or a serious rash.
Rare cases of a brain condition called posterior reversible encephalopathy syndrome (PRES) have been reported in people taking Otulfi (ustekinumab). Symptoms can include headache, seizures, confusion, or vision changes. These symptoms can appear anywhere from a few days to months after starting the medication, sometimes even after a year or more. If you have PRES, your care team will stop the medication and provide treatment. Let your prescriber know right away if you notice any of these signs.
Before starting Otulfi (ustekinumab), you or your child should be up to date on all recommended vaccines. While you're being treated, avoid getting live vaccines. You should also avoid the BCG vaccine during treatment, as well as for one year before starting and one year after stopping the medication. Be careful if someone in your household gets a live vaccine since it can spread and pose a risk to you. Non-live vaccines are generally safe, but they might not work as well while you're taking Otulfi (ustekinumab). Check with your care team before getting any vaccines during treatment.
Different types of pneumonia have been reported in people taking Otulfi (ustekinumab), and in some cases, these conditions were serious. Symptoms can include cough and trouble breathing. Let your care team know right away if you have new or worsening breathing problems. You might have to stop taking the medication and receive the appropriate treatment.
Plaque psoriasis
Adults:
Weight 220 lbs or less: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Weight more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Children ages 6 and older:
Weight less than 132 lbs: The typical dose is 0.75 mg/kg of body weight injected under the skin once, then another 0.75 mg/kg four weeks later. After the second dose, 0.75 mg/kg is injected every 12 weeks.
Weight of 132 lbs to 220 lbs: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Weight more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Psoriatic arthritis
Adults:
Psoriatic arthritis only: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Psoriatic arthritis with plaque psoriasis and weighing more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Children ages 6 and older:
Weight less than 132 lbs: The typical dose is 0.75 mg/kg of body weight injected under the skin once, then another 0.75 mg/kg four weeks later. After the second dose, 0.75 mg/kg is injected every 12 weeks.
Weight of 132 lbs or more: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Psoriatic arthritis with plaque psoriasis and weighing more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Crohn's disease and ulcerative colitis:
Adults:
Weight less than 121 lbs: The typical dose is 260 mg infused into the veins once, then 90 mg injected under the skin every 8 weeks.
Weight of 121 lbs to 187 lbs: The typical dose is 390 mg infused into the veins once, then 90 mg injected under the skin every 8 weeks.
Weight more than 187 lbs: The typical dose is 520 mg infused into the veins once, then 90 mg injected under the skin every 8 weeks.
Moderate-to-severe plaque psoriasis (Ps) - adults and children 6 years and older
Psoriatic arthritis (PsA) - adults and children 6 years and older
Moderate-to-severe Crohn's disease (CD) - adults only
Moderate-to-severe ulcerative colitis (UC) - adults only
Moderate-to-severe plaque psoriasis (Ps) - adults and children 6 years and older
Psoriatic arthritis (PsA) - adults and children 6 years and older
Moderate-to-severe Crohn's disease (CD) - adults only
Moderate-to-severe ulcerative colitis (UC) - adults only
Rheumatoid arthritis (RA) - adults only
Juvenile idiopathic arthritis (JIA) - people age 2 and older
Psoriatic arthritis (PsA) - adults only
Ankylosing spondylitis (AS) - adults only
Crohn's disease (CD) - people age 6 and older
Ulcerative colitis (UC) - people age 5 and older
Plaque psoriasis - adults only
Hidradenitis suppurativa (HS) - people age 12 and older
Uveitis - people age 2 and older
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.